Arcturus Therapeutics Holdings (ARCT) EBT Margin (2018 - 2026)
Arcturus Therapeutics Holdings' (ARCT) quarterly EBT Margin came in at 2746.87% in Q1 2026, down 269896.0% YoY from N/an in Q1 2025, and down 579.66% on a QoQ basis from 404.16% in Q4 2025.
Powered by 
Analysis
Arcturus Therapeutics Holdings (ARCT) EBT Margin (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 9 years of EBT Margin data on file, last reported at 2746.87% in Q1 2026.
- Quarterly EBT Margin fell 269896.0% year-over-year to 2746.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 197.99% (down 15027.0% YoY) and the FY2025 annual result came in at 80.19%, down 2705.0% from the prior year.
- EBT Margin eased to 2746.87% in Q1 2026, from 404.16% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 74.02% in Q4 2022 to a low of 2746.87% in Q1 2026.
- A 5-year average of 312.35% and a median of 69.58% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin soared 300312 bps — and 2026, when it sank 269896 bps.
- Tracing ARCT's EBT Margin over 5 years: stood at 74.02% in 2022, then slumped by 150 bps to 37.09% in 2023, then tumbled by 255 bps to 131.81% in 2024, then sank by 207 bps to 404.16% in 2025, then plunged by 580 bps to 2746.87% in 2026.
- The last three EBT Margin figures came in at 2746.87% (Q1 2026), 404.16% (Q4 2025), and 78.41% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Arcturus Therapeutics Holdings | 449.65 Mn | 258.17 Mn | - | -803.82% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -803.82% |
| Mar 31, 2026 | -1,403.74% |
| Dec 31, 2025 | -404.16% |
| Sep 30, 2025 | -78.41% |
| Jun 30, 2025 | -32.42% |
| Mar 31, 2025 | -47.91% |
| Dec 31, 2024 | -131.81% |
| Sep 30, 2024 | -17.09% |
| Jun 30, 2024 | -34.83% |
| Mar 31, 2024 | -69.58% |
| Dec 31, 2023 | -37.09% |
| Sep 30, 2023 | -33.96% |
| Jun 30, 2023 | -494.09% |
| Mar 31, 2023 | 63.35% |
| Dec 31, 2022 | 74.02% |
| Sep 30, 2022 | -263.79% |
| Jun 30, 2022 | -79.59% |
| Mar 31, 2022 | -975.76% |
| Dec 31, 2021 | -649.72% |
| Sep 30, 2021 | -2,208.49% |